Search This Blog

Saturday, January 4, 2020

Reading new nutrition facts labels

The Food and Drug Administration has updated the Nutrition Facts label on packaged foods and beverages to reflect new scientific information, including the link between diet and chronic diseases. Manufacturers with $10 million or more in annual sales were required to switch to the new label by Jan. 1, 2020. Here, Angie Murad, a wellness dietitian with the Mayo Clinic Healthy Living Program, explains some of the key changes.
The new design of the Nutrition Facts label is meant to make it easier for consumers to make informed  choices. One of the most noticeable changes is the calories are now in a larger, bolder type.
“That can be helpful when you’re trying to identify how many calories are in a product,” Murad explains.
When comparing calories and nutrients in different foods, you should check the serving size. However, since how much people eat and drink has changed over the years, the food serving sizes are getting a reality check on the new labels.
“It may not be an example of what one serving is, but it may be more realistic of what someone really is eating so they can pinpoint exactly how many calories something has,” says Murad.
The new labels are now required to include vitamin D, potassium and added sugars. When making healthy , Murad says to look at the calories.
“They should look at added sugars. You want to be looking for things that have  and staying away from things that have high saturated fats.”

1 on 1 with CMS chief Seema Verma

KEY TAKEAWAYS

‘There’s a balance between making sure it’s easy for people to apply, but we also have to make sure that we do the appropriate work to make sure that they qualify for the programs.’
‘Medicare for All would strip Americans, 180 million Americans, of their private health insurance and put them on a government-run, bureaucratic program.’
‘As the head of the Medicare program, I see every day that government regulations kind of stand in the way.’

Seema Verma, administrator for the Centers for Medicare & Medicaid Services, sat down for a rare one-on-one interview with Kaiser Health News senior correspondent Sarah Varney.
They discussed her views on President Donald Trump’s plan for sustaining public health insurance programs, how the administration would respond if Obamacare is struck down by the courts in the future and her thoughts on how the latest “Medicare for All” proposals would affect innovation and access to care. A transcript follows, edited for length and clarity.
Sarah Varney: Thank you, Administrator Verma, for joining us. We really appreciate it. You spoke recently about this need to protect Medicaid as a lifeline, but also not to have people be entrapped, or trapped on, Medicaid and come to rely upon it too greatly. So, as I was mentioning, we were in Tennessee recently, and I know you can’t speak to specific cases —
Seema Verma: Mmm, hmm.
Varney: But, we did find a number of families who had been disenrolled, and then found it quite difficult to get back on. And I just wondered if there is a danger in taking this approach where there’s more frequent verification checks, a real focus on eligibility verification, that it could discourage some parents and kids who might be eligible for the program from signing up?
Verma: Well, our top priority is making sure that the beneficiaries in the Medicaid program have high-quality, accessible care, and we want to do everything that we can to improve the quality of their lives. In terms of the enrollment process, we also have an obligation to taxpayers to make sure that only the people that qualify for the programs are participating. And we also want to make sure that the programs are sustainable over the long term. I think there’s a balance between making sure it’s easy for people to apply, but we also have to make sure that we do the appropriate work to make sure that they qualify for the programs.
Varney: So, are you concerned, though, that there were a number of people, after the eligibility process kicked in again in 2017, after the ACA sort of put things on hold for a while, that there might have been families, though, that have been lost? That just don’t want to come back, or can’t come back? Or are hearing worries about the public charge rule, as well, and so are concerned about giving the government their information?
Verma: You know, our top priority is making sure that we focus on improving quality of care, high-quality care, accessible care, and making sure that we’re improving the quality of life for individuals. You know, when I think of the Medicaid program, and in every decision we make, I try to keep in mind the actual beneficiary. In my time spent on the Medicaid program, I’ve met a lot of Medicaid beneficiaries. I met a gentleman, Richard, who was in Indiana. He was a quadriplegic and literally requires 24-hour care. I met some parents of a child on the Medicaid program. This child had cerebral palsy and so severe that they require 24-hour care, and you can imagine the impact on the entire family. This is a child that will never be independent, will always require help. And so, when we’re creating our eligibility policies, we keep those individuals in mind. We don’t want to make it harder for them to apply for the program.
And so, we try to come up with policies that don’t put a lot of onerous requirements on the beneficiary, but we can have requirements for states that require them to do back-end processes, and back-end checks that don’t actually burden the actual recipient or their families, but that also ensure that we are putting the appropriate protections in place for taxpayers, so the program is sustainable over the long term. And we have only the people that qualify for the program participating.
Varney: We know that more health coverage leads to longer life expectancy; I think this has been well established. And I wonder if whether or not the administration should be emphasizing more finding those children who are not enrolled, who are eligible but not enrolled, and perhaps focusing on outreach, which we haven’t really heard your administration talk about?
Verma: Well, again. Our focus is on making sure, especially children, that they have access to high-quality health care. As a mom, I’ve got two kids, so I can personally attest to the fact that having health insurance is very important for children. Something very little, like an ear infection, can lead to deafness if it’s not, you know, treated appropriately. So having that access to high-quality health care is very, very important to their development. The Trump administration is very committed to the Children’s Health Insurance Program; the president signed legislation around that. Additionally, we have spent over $48 million on outreach efforts. We’re very focused on working with states, so that they can identify the best practices to make sure that those individuals, children that qualify, can enroll in the program, that they’re aware that this program exists.
Varney: Have you found that the reduction in the Navigator grants has made it more difficult to reach those families?
Verma: We, actually, we have not. If you look, the Navigator programs are really aimed at the Affordable Care Act programs and the exchange programs. So those are not aimed at children. Those are aimed at our adult population. And we have seen very minimal impact. What we have done is try to increase our digital communication, of, to help enrollment. And we’ve seen a very minimal impact on enrollment.
I think the issue around enrollment really comes back to affordability. Obamacare has had a direct impact on increasing premiums. Across the nation, we’ve seen premiums go up by 100%, 200%. [Editor’s note: PolitiFact rated this claim by the Trump administration “false.” ACA premiums were down by about 4% in 2019 compared with 2018.] And so the issue around enrollment is that health insurance has become so unaffordable for families that that’s why they can’t afford their coverage.
Varney: So we did hear from a number of federally qualified health centers that although the Navigator grants really were focused on, you know, ideally they were focused on exchanges, people buying private health insurance, that, in fact, there were a lot of people who came in, who became eligible for Medicaid and discovered that they were eligible for Medicaid in that way. So I wonder if there is additional outreach that needs to be done to those families, not just virtually or online, but some other way to reach those families?
Verma: The real problem around making sure that people have access to affordable coverage is really addressing the high cost of health care. And that’s what the president is focused on. His health care agenda isn’t just about putting out more subsidies and having the government pay more and more and creating unaffordable programs. But it is about addressing the underlying cost drivers in health care. That’s why he’s focused on prescription drug pricing, he’s focused on transparency, price transparency, so that there’s more competition in the market. We’re also focused on getting rid of burdensome regulations that we know drive up the cost of care.
I think by addressing that, that is going to result in decreased premiums, which will result in more people having access to affordable coverage.
Varney: But all those things that you just mentioned — they don’t necessarily affect the Medicaid population directly. Now, they may affect them indirectly by increasing overall health care costs, but in terms of the Medicaid population, really reaching out, ensuring that every single child who’s eligible for Medicaid is enrolled?
Verma: So, our focus is also on addressing the economy. Under the president’s leadership, we have a booming economy. We have one of the lowest unemployment rates. We have more people that are earning more money, and we have fewer people living in poverty. There’s been a reduction in the number of people living in poverty by 1.4 million people. And so, we are seeing people coming out of the Medicaid program, and because the economy’s doing so well. The issue is, though, they can’t afford coverage. And so, even as we increase our outreach efforts, we spent over $48 million on outreach, the issue is around affordability. Obamacare has impacted the market in such a way that it’s become unaffordable for people that don’t have subsidies.
Varney: So, we’re at this moment in our country and our national conversation where we’re talking about how do we ensure that more and more people are insured? And I wonder what the administration is doing to move the needle, to stop the growth in the uninsured, particularly among children?
Verma: I think our focus has been about addressing affordability of health care. The underlying issue in people not being able to afford their health insurance is that it’s too expensive. And the solution is not trying to throw more government money around subsidies, because that’s just going to increase taxes for everybody. Our approach is to address the underlying issues. President Trump is addressing long-standing issues in health care that haven’t been addressed by any administration. The blueprint that he put out on drug pricing was very historic. The work that he’s done on price transparency. And the work that we’re trying to do around the regulatory burden, getting rid of all kinds of unnecessary regulations that are actually increasing the cost of health care for providers. We spend over $200 billion on administrative costs every year. So what we’re trying to do is address the cost of health care, but also make sure that we continue to have the high-quality, innovative health care system that Americans are used to.
Varney: So there are some people who are advocating for a Medicare for All type of solution to this, to say that much of those costs are because the marketplace, in a sense, doesn’t work in health care. And I wonder what you say to people who are proposing that? Who are saying, this is all just, that the market doesn’t work when it comes to health care?
Verma: So, when it comes to health care and it comes to the solutions around Medicare for All. … Medicare for All would strip Americans, 180 million Americans, of their private health insurance and put them on a government-run, bureaucratic program. If we look at the programs that we have today, our government-run programs, our Medicare program is not affordable. The Medicare Trustees have indicated in the next seven years they’re gonna run out of money, they’re gonna have trouble paying their bills. The Medicaid program is the No. 1, No. 2 budget item for many states. And you’re hearing states every day — look at the situation in New York, where they can’t afford their Medicaid programs. And so, our track record on government-run programs isn’t strong. And I think our focus is on trying to unleash competition to drive down costs, but keep the innovation in the system. Our concern is that a government-run or more government is going to thwart innovation.
As the head of the Medicare program, I see every day that government regulations kind of stand in the way, that there are delays in our beneficiaries being able to access treatments. That’s why the president put out the Medicare Executive Order, which was focused on making sure we can do better with this. But I think, you know, putting more people on a government program is actually going to threaten the sustainability of the programs that we have in place today.
Varney: And do you think through the measures that you’re talking about, that you could reduce costs — 15%, 20% — in the health care system of the United States?
Verma: I think our goal is to try to reduce cost, and to make it more unaffordable [sic]. And we’ve had great success with this under President Trump’s leadership. If we look at the Medicare Advantage Program, for example, under his leadership, premiums have gone down by over 23% since he came into office. In the Part D program, premiums are down by 13%, the lowest level in seven years. Going back to Medicare Advantage, that’s the lowest level in 13 years. So, I think the president’s policies are working, because we demonstrated that we can lower premiums.
Same thing on the individual exchanges. For the very first time, the individual market has been stabilized and premiums went down last year by a percent, this year by 4%, and they’re still too high, there’s a new class of uninsured being created by Obamacare, but President Trump’s policies have actually resulted in more Americans, more seniors having money back in their pockets.
Varney: Now we’re waiting for a ruling from the courts on the future of the Affordable Care Act. If it’s struck down, what is your plan to replace it?
Verma: Well, the president’s been very clear that he wants to make sure that individuals with preexisting conditions have protections. And we have prepared for a variety of scenarios, and we want to make sure that there’s no disruption in coverage. And we’ll work with Congress to make sure that Americans have access to high-quality, affordable coverage. That is not what they have today. People with preexisting conditions do not have those protections. Individuals that don’t get subsidies and can’t afford coverage really don’t have those protections. And so the president wants to make sure that we’re addressing those individuals, and that people with preexisting conditions have the appropriate protections that they don’t have today.
Varney: But how do you guarantee those protections, also reduce costs and not lead to widespread uninsurance rates going up?
Verma: I think our focus is not just on costs, but it’s also making sure that we preserve quality and innovation in the system. One of the initiatives that we’ve had is around trying to pay our providers differently. Right now, we’re paying in a system where we just pay for people to get things done. And we want to change that paradigm, where we’re holding providers accountable for providing quality care, improving the quality of life, preventing disease and keeping people healthy.
Varney: So, just my final question. There have been these reports of a rift, a growing rift between you and Department of Health and Human Services Secretary Alex Azar. And I wonder if people should be concerned about whether or not that’s going to get in the way of the very ambitious slate of initiatives that you and President Trump have planned?
Verma: Well, Secretary Azar and I are both committed and have a shared goal around delivering on the president’s agenda.

Halting ALS with a gene therapy approach

An abnormality in the SOD1 gene is linked to some inherited cases of amyotrophic lateral sclerosis (ALS). So could turning off the mutated gene halt the disease? An international research team led by the University of California San Diego School of Medicine showed the potential of that strategy in mice by using a gene therapy approach.
A one-time injection of a gene-silencing RNA delivered by an adeno-associated virus (AAV) vector into the spinal cord prevented the onset of ALS in presymptomatic mice, and it blocked disease progression in rodents that had already developed symptoms. The team reported the findings in the journal Nature Medicine.
The SOD1 gene codes for an enzyme called superoxide dismutase. Normally, the enzyme breaks down superoxide radicals that are produced during cell metabolism. But in ALS, SOD1 mutations can create misfolded SOD1 protein, as toxic oxygen molecules persist, leading to the death of motor neurons.
The UC San Diego-led team postulated that a short hairpin RNA (shRNA)—an artificial RNA molecule that can silence gene expression—could be utilized to block the dysfunctional SOD1 gene.
Other researchers had tried delivering shRNA-bearing vectors into the blood via intravenous injection. In mouse models of ALS, disease progression was indeed slowed, but the approach only extended survival by about three months. In a more recent study, scientists used intrathecal injection into the cerebrospinal fluid, but the animals lived only two months longer despite being treated immediately after birth.
For the current study, the UCSD researchers injected the shRNA-containing AAV therapy into the spinal subpial space at cervical and lumbar spine levels.
The team observed impressive results. Remarkably, SOD1-mutated mice treated before disease onset never developed disabilities related to motor neuron functions when followed to an average age of 462 days. That means they didn’t lose functions like grip strength or orientation reflexes. The control animals, by contrast, started showing symptoms at about 306 days and reached the end-stage of ALS about three months later.
Further analysis showed that the therapy suppressed the accumulation of misfolded SOD1 protein and almost completely preserved motor neuron cells.
In mice that had already entered the symptomatic stage, the injection also blocked disease progression and further motor neuron degeneration, the team reported.
“At present, this therapeutic approach provides the most potent therapy ever demonstrated in mouse models of mutated SOD1 gene-linked ALS,” the study’s senior author, Martin Marsala of UCSD, said in a statement.

Several other strategies have been developed aimed at decreasing the production of mutated SOD1 protein. Swiss biotech Neurimmune has a recombinant antibody called α-miSOD1, which the company developed based on memory B cells that are found in healthy elderly people and that protect against misfolded SOD1. In mouse models of ALS, the drug extended the animals lives by up to two months.
Antisense oligonucleotide therapy is another potential modality for fighting neurodegenerative disease. Biogen recently showed its antisense drug tofersen (BIIB067) was well tolerated in ALS patients in a small phase 1 study. At its highest dose, the drug cut SOD1 protein levels in spinal fluid and the patients performed well on certain clinical function tests.
Marsala and colleagues now plan to run additional studies of their spinal subpial shRNA approach in a large animal model to determine the optimal, safe dosage of the treatment.
“In addition, effective spinal cord delivery of AAV9 vector in adult animals suggests that the use of this new delivery method will likely be effective in treatment of other hereditary forms of ALS or other spinal neurodegenerative disorders that require spinal parenchymal delivery of therapeutic gene(s) or mutated-gene silencing machinery, such as in C9orf72 gene mutation-linked ALS or in some forms of lysosomal storage disease,” Marsala said in the statement.

At CES, tech will show how it’s the key to value-based care

Twenty-five years ago, stem cell research was still in its infancy. Health records were only just going from paper to computer. Telehealth was nonexistent.
Today, people are living longer, doctors are conducting surgeries from across the world, and we can get diagnoses and order prescriptions online, without ever having to enter a doctor’s office.
Yet, for all these advancements, the health care industry remains stuck in an incentive structure that encourages – and even rewards – practitioners for over-testing or pushing unnecessary treatments. Technology is improving the accuracy and efficacy of treatment, but bureaucratic precedence often wins.
We need a better approach.
Value-based healthcare — in which health care providers are paid based on outcomes, not services rendered — may be the answer.
This “quality over quantity” model can make health care more effective and more affordable (a much-needed change, considering health care costs in the U.S. skyrocketed to $3.65 trillion last year). If done right, it can incentivize doctors to provide quality care and cut back on over-testing, and empower patients to take control of their wellness. And it can address physician and caregiver shortages and unburden health care by making it easier for the millions of Americans to age in their homes rather than be institutionalized.

As consumers and leaders in the public and private sectors look to the future of health care, we must keep in mind what’s on the technological horizon that will help bring this future to life. Advancements in digital health address some of the most pressing global issues of our generation, including opioid dependence, mental illness and chronic disease.
CES 2020 — the world’s largest, most influential technology event — will showcase hundreds of the newest technologies poised to disrupt the health care industry. Companies including Philips, Omron Healthcare, Myant, P&G, Cigna, Humana and Johnson & Johnson will present their newest products and cutting-edge research. And CES will partner with the American College of Cardiology Foundation to offer continuing medical education (CME) credits to doctors, nurses and other medical professionals to highlight tech innovations creating solutions for patient care.
Here are some of the technologies you’ll see at CES 2020 this January that can help make value-based care a reality:
Remote patient monitoring
Remote patient monitoring technology makes earlier diagnoses, better outcomes and cost savings available to more and more patients. According to a recent CTA survey, two in three physicians intend to use remote patient monitoring technology to manage their patients’ health in the future.
With remote patient monitoring, wearables such as CarePredict’s Tempo for seniors can provide customized care such as serving as a call button, tracking food, water, and medicine intake and noting a senior’s location. Another innovation designed to help seniors is Electronic Caregiver, providing remote monitoring to ensure safety and wellness – and give family members and loved one’s peace of mind. Other apps can remind diabetes patients to take their insulin or allow physicians to monitor glucose levels over time. And technology such as Omron’s blood pressure monitor can actively track heart health.
The need for increased accuracy and cost savings has driven the demand for remote monitoring from both physician and payer perspectives. Through sensor innovation and miniaturization, consumer-grade monitoring/diagnostic devices are becoming more accurate and easier to wear and use — and we’ll see smaller, less invasive and more sensitive devices this year. The cost savings of adopting these devices should easily make the requisite patient education processes worthwhile.
Digital therapeutics
Digital therapeutics are a new breed of digital health devices enabling patients with chronic disease to better adhere to treatment protocols and providing doctors with more data on the effectiveness of various treatments. Digital therapeutics can provide personalized care programs based on a patient’s needs and abilities to prevent and manage conditions and diseases — from asthma, diabetes and Alzheimer’s to hypertension, ADHD and mental health issues — and reduce reliance on certain pharmaceuticals or other therapies. One such device is a product from Carrot Inc. called Pivot, which is a smoking cessation program that uses an FDA-cleared mobile breath sensor, consumer-grade mobile app, behavioral science and personal coaching to help individuals quit smoking.

With digital therapeutics, patients can receive daily in-home physical exercises. They can track their fitness and food intake to prevent the onset of diabetes and control obesity. They can measure their blood sugar levels. And they can receive motor, speech or cognitive behavioral therapy at home, through web-based applications or digital dashboards. Other technologies can monitor sleep patterns and provide access to personalized suggestions to improve sleep. Ebb Therapeutics, for example, develops products that help patients with insomnia through temperature sensing and control.
Virtual reality
New virtual reality (VR) technologies allow doctors to better perform surgeries remotely, or train doctors on new skills with immersive training tools. Robotic surgeries, used in the right context, are increasingly more accurate and mean smaller incisions. And VR means doctors can show patients exactly how their surgeries will happen, using virtual reconstructions of their own bodies. Simulators from Samsung can help patients with pain management, and VR games help patients keep on track with their physical therapy.
Patients and doctors alike realize expensive testing and treatments with minimal (or no) results are not always worth the time, cost or pain. The future of health care is lower costs, more accessible care and better outcomes.
Value-based care will be an important step toward reducing chronic disease and improving overall wellness.
And at CES, we see the new tools and technologies poised to enhance the patient experience and transform the future of health care.
Gary Shapiro is president and CEO of the Consumer Technology Association (CTA), the U.S. trade association representing more than 2,000 consumer technology companies.

Texas judge: Hospital can remove baby from life support

A Texas judge on Thursday sided with a hospital that plans to remove an 11-month-old girl from life support after her mother disagreed with the decision by doctors who say the infant is in pain and that her condition will never improve.
Trinity Lewis had asked Judge Sandee Bryan Marion to issue an injunction in Tarrant County district court to ensure that Cook Children’s Medical Center doesn’t end her daughter Tinslee Lewis’ life-sustaining treatment. Texas Right to Life, an anti-abortion group that is advocating for Tinslee, said the girl’s mother will appeal the judge’s decision.
Doctors at the Fort Worth hospital had planned to remove Tinslee from life support Nov. 10 after invoking Texas’ “10-day rule,” which can be employed when a family disagrees with doctors who say life-sustaining treatment should be stopped. The law stipulates that if the hospital’s ethics committee agrees with doctors, treatment can be withdrawn after 10 days if a new provider can’t be found to take the patient.
In a statement issued by Texas Right to Life, which opposes the “10-day rule,” Lewis said she was “heartbroken” over the judge’s decision. “I feel frustrated because anyone in that courtroom would want more time just like I do if Tinslee were their baby,” she said.
The hospital said in a statement Thursday that in order to keep Tinslee alive, she’s on a constant stream of painkillers, sedatives and paralytics. She currently has severe sepsis, which isn’t uncommon when patients require deep sedation and chemical paralysis, it said.
“Even with the most extraordinary measures the medical team is taking, Tinslee continues to suffer,” the hospital said.
Efforts to find another facility to take her have been unsuccessful. The hospital said it has reached out to more than 20 facilities. Texas Right to Life and Protect TX Fragile Kids have also been trying to find a facility to take her.
Prior to Thursday’s ruling, both sides agreed that if Marion denied the injunction request, the hospital would wait at least seven days before taking Tinslee off life-support. In her decision, Marion said the seven-day period would give the girl’s mother time to file a notice of appeal and a motion for emergency relief with a state court of appeals.
Tinslee has been at Cook Children’s since her premature birth. The hospital said she has a rare heart defect and suffers from chronic lung disease and severe chronic high blood pressure. She hasn’t come off a ventilator since going into respiratory arrest in early July and requires full respiratory and cardiac support.
Lewis testified at a hearing last month that despite her daughter’s sedation, she has a sense of the girl’s likes and dislikes, describing her as “sassy.” She said Tinslee likes getting her nails done but doesn’t like having her hair brushed.
“I want to be the one to make the decision for her,” Lewis said about removing her daughter from life support.
At the hearing last month, Dr. Jay Duncan, one of Tinslee’s physicians, described the girl’s complex conditions and Cook Children’s efforts to treat her, which have included about seven surgeries. The cardiac intensive care doctor said that for the first five months of Tinslee’s life doctors had hope she might one day at least be able to go home.
But Duncan said there came a point when doctors determined they had run out of surgical and clinical options, and that treatment was no longer benefiting Tinslee. Duncan said last month that the girl would likely die within half a year, and noted the hospital has made “extraordinary” efforts to find another facility for her.
“She is in pain. Changing a diaper causes pain. Suctioning her breathing tube causes pain. Being on the ventilator causes pain,” he said.
Duncan said there had been “many, many” conversations with Tinslee’s family about her dire condition.
Tarrant County Juvenile Court Judge Alex Kim issued a temporary restraining order to stop the removal of life support on Nov. 10. But Kim was removed from the case after the hospital filed a motion questioning his impartiality and saying he had bypassed case-assignment rules to designate himself as the presiding judge.
After his removal, Judge Marion, who is chief justice of Texas’ Fourth Court of Appeals, was assigned to hear the request for an injunction in Tarrant County district court.
The case has become a rallying point for Republicans in Texas, with the attorney general stating his opposition to the “10-day rule” and GOP state Rep. Tan Parker saying it “doesn’t fit with Texas values.”
The 1999 law that shields from lawsuits doctors who follow the process of going through an ethics committee was crafted by a task force that included lawmakers, attorneys, doctors and anti-abortion groups. Supporters of the law passed when George W. Bush, a Republican, was governor include the Texas Alliance for Life, the Texas Catholic Conference of Bishops and the Texas Medical Association.
Supporters say the law provides a framework for doctors and hospitals to resolve differences and ensures that doctors can’t be forced to perform medical interventions that cause harm or suffering.

Two blockbuster cancer drugs see New Year price hikes

Drugmakers raised prices on more than 400 drugs in the early days of 2020, including two blockbuster cancer treatments that have been top-expenditure drugs in Medicare Part B, according to healthcare analysts and CMS data.
The CMS attributed an increase in Part B premiums and deductibles in 2020 to increased spending on physician-administered drugs. Part B premiums and deductibles both rose 7% compared with 2019 levels.
Two of the 10 physician-administered drugs that Medicare spent the most money on in 2018 have seen price increases this January, healthcare research firm 3 Axis Advisors found. While providers may not pay the sticker price for drugs in Part B, beneficiary cost-sharing is tied to list prices.
Merck instituted a price increase of 1.5% for Keytruda, the second-highest expenditure Medicare Part B drug in 2018. Bristol-Myers Squibb increased the price for Opdivo, a drug used to treat small cell lung cancer, by 1.5%. Opdivo was the third-highest Part B expenditure drug in 2018.
More price hikes could come later in the month as drugmakers delay customary price hikes to avoid scrutiny. Drugmakers can increase prices at any time.
GoodRx, a company that helps consumers find lower prices on medicines at pharmacies, noted that the average January 2020 drug price increase so far is 5%, compared with 5.2% in 2019 and 8% in 2018.
The Medicare Payment Advisory Commission reported in June that two-thirds of Medicare Part B drug spending growth between 2009 and 2016 was attributable to prices, including price hikes on existing drugs and the launch prices of new drugs.
Even though price increases seem to be moderating in recent years, research by a not-for-profit run by 3 Axis co-founders showed launch prices for new brand-name drugs have risen significantly since 2006, according to one of the co-founders, Antonio Ciaccia.
“Our research has shown that launch prices are what have been growing while the de-emphasizing of increases on pre-existing drugs has occurred,” Ciaccia said.
Top House and Senate lawmakers used the 2020 price hikes to push their colleagues to pass major drug-pricing legislation this year, including measures that could reduce spending on physician-administered drugs.
Senate Finance Chair Chuck Grassley (R-Iowa) tweeted on Thursday to promote a policy that would force drugmakers to pay back Medicare for price hikes that outpace inflation in Medicare Parts B and D. That policy was included in legislation he authored with Finance ranking member Ron Wyden (D-Ore.), but it has proved a nonstarter for some Senate Republicans who view the policy as a form of price controls.
preliminary analysis by the Congressional Budget Office estimated that the Grassley-Wyden inflationary rebates in Medicare Part B would save the federal government $10.7 billion over a decade. A similar policy for retail prescription drugs has estimated savings of $57.5 billion, as retail drug spending makes up a much larger portion of overall Medicare spending.
House Speaker Nancy Pelosi (D-Calif.) also used the price hikes to call for passage of her drug price negotiation bill. House Democrats’ proposal includes an inflationary rebate policy similar to the Grassley-Wyden bill, though prices are indexed to 2016 prices instead of 2019 in the Senate legislation.
The Campaign for Sustainable Rx Pricing, which includes members such as the American Hospital Association, the Federation for American Hospitals, Kaiser Permanente and several insurers, called for legislative action to address drug prices in response to the 2020 price increases.
“With an election approaching, the clock is already ticking. Lawmakers, in both parties, will need to work diligently to deliver relief for American patients,” CSRxP executive director Lauren Aronson said.
An HHS spokesperson said the Trump administration “remains steadfastly focused on lowering drug prices even further and ending foreign free-riding.”
The administration has not yet proposed a demonstration that would tie payment for some Medicare Part B drugs to prices in foreign countries. The policy has been under review at the Office of Management and Budget since June 2019.

Hospitals Exploring Short-Term Housing For Homeless Patients


Hospitals Exploring Short-Term Housing For Homeless Patients To Free Up Beds
Hospitals around the country are seeking to reduce their bed counts to cut costs, but the most economically vulnerable patients present a unique obstacle that is only just beginning to be addressed.
The American Hospital Association and a number of regional hospital systems have begun initiatives to build temporary housing for homeless patients or those experiencing housing instability, Fox News reports.
For hospitals with a mandate not to discharge patients straight to the street or deny care based on ability to pay, a basic apartment could be much cheaper to operate than a hospital bed.
As well-funded hospitals sink billions into new construction and renovation to keep costs low, hospitals that serve Medicare- and Medicaid-covered populations have been struggling to keep the lights on in recent years due to spiraling costs.
Some creative solutions have begun to emerge at the local level. The Denver Housing Authority is partnering with Denver Health to renovate a vacant building on the latter’s main campus into low-income senior housing, but the hospital is leasing back one of the floors to create 15 transitional units, Fox News reports. Patients that would otherwise remain in the hospital due to uncertainty over their next living situation would be placed in the units while permanent housing of some sort is lined up.
Denver Health expects the units to cost $10K per patient each year, compared to the $2,700 per day for a hospital bed, Fox News reports.
AHA is currently working in 10 markets across the U.S. as part of its Hospital Community Cooperative Program to address social issues like housing instability that negatively impact health outcomes, Fox News reports. The organization projects that social inequities, including housing, will cost the country’s healthcare system $126B this year.
Safety net hospitals in urban and low-income areas bear a greater portion of those costs than facilities in affluent communities, since Medicare and Medicaid pay much less for care than most private insurers.
On top of that, nearly 28 million non-elderly Americans have no health insurance, according to a Kaiser Family Foundation report released in December.
The University of Illinois Hospital & Health Sciences System has put hundreds of thousands of dollars into a pilot program called Better Health Through Housing that discharges homeless hospital patients in its Chicago-area facilities to a network of living units with “intensive case management,” Fox News reports. The program is set to expand this year to 75 patients from its starting number of 26.